• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Haematologica >A new kid on the block for acute myeloid leukemia treatment? Homoharringtonine interferes with key pathways in acute myeloid leukemia cells
【2h】

A new kid on the block for acute myeloid leukemia treatment? Homoharringtonine interferes with key pathways in acute myeloid leukemia cells

机译：一个正在接受急性髓细胞白血病治疗的新孩子？同型harringtonine干扰急性髓性白血病细胞的关键途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment for acute myeloid leukemia (AML) has not changed substantially in the past 40 years. We still largely rely on the substances (antimetabolites and topoisomerase inhibitors) that were introduced for AML treatment in the 1970s. Although treatment outcomes for AML, other than acute promyelocytic leukemia (APM), have improved over the years, these improvements have been slow and incremental and been largely achieved by optimizing dosing schedules and better supportive care. However, substantial improvements in treatment, with high cure rates, have been achieved in genetically well defined subgroups of leukemia like acute promyelocytic leukemia (driven by the PML/RARA fusion) and chronic myeloid leukemia (driven by the BCR/ABL fusion). AML, however, is a different beast. It is not a single disease but a genetically highly heterogeneous group of malignant diseases of the hematopoietic stem cell that have similar phenotypes. The great genetic heterogeneity of AML, which was recognizable even in the early cytogenetic studies, has become very apparent with the advent of next-generation sequencing which has allowed the analysis of AML genomes at base pair resolution.
机译：在过去的40年中，急性髓细胞性白血病（AML）的治疗方法并未发生重大变化。我们仍然很大程度上依赖于1970年代用于AML治疗的物质（抗代谢物和拓扑异构酶抑制剂）。尽管这些年来，除急性早幼粒细胞白血病（APM）以外，AML的治疗结局已有所改善，但这些进展缓慢而渐进，并通过优化给药方案和更好的支持治疗而取得了很大的进展。然而，在遗传上明确定义的白血病亚组，例如急性早幼粒细胞白血病（由PML / RARA融合驱动）和慢性髓细胞性白血病（由BCR / ABL融合驱动），已在治疗上取得了显着改善，治愈率很高。但是，AML是另一回事。它不是单一疾病，而是具有相似表型的造血干细胞恶性疾病的遗传高度异质性组。 AML的巨大遗传异质性，即使在早期的细胞遗传学研究中也可以识别，随着下一代测序技术的出现已变得非常明显，该技术已使AML基因组能够以碱基对的分辨率进行分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号